On innovations and technologies
Published on 29 September 2020 by Anna Andriyanova
Katerina Pogodina, Director General,
Johnson & Johnson LLC; Managing Director, Janssen Russia and CIS
These days, the value of innovations in every single person's life is more evident than ever. Innovative technologies have always been the driving force for the pharmaceutical industry, as only continuous research and development allows us to provide patients with effective and modern treatment of diseases — even those that we used to think were incurable.
Now the whole world is anticipating the COVID-19 vaccine. To make this happen, the best researchers work tirelessly under aggressive deadlines, focusing their efforts on finding molecules and combinations that can stop the spread of the pandemic. Johnson & Johnson scientists are no exception. In January 2020, they were among the first to begin searching for a potential COVID-19 vaccine. And in this regard, I want to emphasize the enormous role that international partnership plays in the inquiry, research, and development process.
During the COVID-19 pandemic, humanity never stops fighting other diseases. There are patients with cancer, orphan diseases, emergency conditions, and these patients need help right here and right now. That is why we may never stop working on innovations. Over the past ten years, science has evidently made great strides forward, especially in medical care. After all, now personalized medicine is becoming more and more available to patients, and it can improve the results of drug therapy and the patient's quality of life, as well as reduce the number of adverse events. Such therapy is vital for patients with chronic conditions and diseases that are difficult to treat. We focus precisely on such therapeutic options and strive to improve both the drugs themselves and the methods of their delivery.
Speaking about innovations, the topic of digitalization should be mentioned. The COVID-19 pandemic has become a catalyst for developing and implementing digital solutions.
With the pandemic and the increased pressure on the health care system, the tremendous value of digital opportunities became obvious. Digitalization in the health care sector includes medical care management, as well as the use of big data to make more balanced medical decisions. It means introducing techniques based on artificial intelligence, and the potential for the transition to personalized healthcare and increasing the stability of the system as a whole, and much more.
Prioritizing digitalization at a high political level is encouraging. In this regard, the challenge facing the industry is to provide patients with convenient service and quality treatment. So, for example, experts are working hard on creating a unified register of patients, which will be introduced into the general system of the Unified State Health Information System. Aggregating big data in compliance with all the personal data protection regulations offers many opportunities and may help doctors make better decisions and choose more person-specific treatment strategies in the future. It is extremely important that this innovation process continues.
I am convinced that having an effective ecosystem to protect intellectual property rights is the foundation for innovation development in any area — from the heavy mining industry to pharmaceuticals and information technologies. Not only innovation and technology make it possible to solve those healthcare problems that seemed unresolvable only 10 years ago but also allow us to ensure the sustainability of the system as a whole. And we must commit ourselves to maintain this ecosystem.
As a company, we are responsible for the community where we live and work. We want to and must help make it easier for people around the world to take care of their health, and innovative technology is our best and most reliable ally along the way.